echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Survival prognosis for glial sarcoma is associated with MGMT promoter methylation and temozolomide

    Survival prognosis for glial sarcoma is associated with MGMT promoter methylation and temozolomide

    • Last Update: 2022-09-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Vasileios K.



    ——Excerpt from the article chapter


    【Ref: Kavouridis VK, et al.



    Research background

    Gliosarcoma (gliosarcoma), which accounts for about 2% of glioblastoma (GBM), is an uncommon subtype of glioblastoma whose histological characteristics consist of




    The authors searched the National Cancer Database for patients


    Research results

    A total of 580 newly diagnosed patients with glial sarcoma had MGMT status, of which 33.


    Conclusions of the study


    In summary, the study found that the methylation rate of the MGMT promoter of glial sarcoma is about 1/3, which is lower




    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.